BRTX - Notable Newsmakers
2024-04-16 09:29:31 ET
DENVER, Colo., Apr 16, 2024 ( 247marketnews.com )- Palisade Bio, Inc. (Nasdaq: PALI ), Brera Holding (NASDAQ: BREA ), Peraso Inc. (NASDAQ: PRSO ), BioRestorative Therapies, Inc. (NASDAQ: BRTX ), and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI )
Palisade Bio, Inc. (Nasdaq: PALI ) stated that it successfully completed its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC, demonstrating that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.
“The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC,” stated Dr. Mitch Jones, Palisade Bio’s CMO. “The successful bioactivation of prodrug PALI-2108 into its active PDE4 inhibitor form at consistently high conversion rates over a 24-hour period in stool samples highlights its promise as an innovative therapeutic approach for managing UC.”
Brera Holding (NASDAQ: BREA ) is actively scouting to acquire the next piece of their multiclub ownership (MCO), professional football team puzzle, which could include some well-known names.
“The acquisition of a professional football club will demonstrate our ability to execute the MCO model at the highest level, and we are eager to announce the transaction details when finalized,” said Brera Holdings CEO, Pierre Galoppi. “In addition to acquiring clubs that have significant upside potential, our goal is to partner with clubs that share our fundamental belief in player culture and development. By aligning Brera with high profile clubs and partners who share our vision, we believe it will unlock several layers of player progression and deliver new revenue streams by building champions, as opposed to buying them,” Galoppi concluded.
Famed Investment Banker, Daniel McClory, took a large position in Brera, which operates in a space that is projected to be a top asset class.
To address this dynamic, Goldman Sachs (NYSE: GS ) , which worked on Chelsea Football Club and Formula One deals, created a Sports Franchise unit, within its investment banking division, to provide wealthy clients with opportunities to invest in sports team financing, while JP Morgan (NYSE: JPM ) recently established a Sports Investment Banking division and reported “The sports sector has evolved into a significant asset class, drawing an increasing number of institutional investors.”
According to the WSJ, “Limited supply is one of the main attractions of investing in sports teams, as opportunities arise only when team owners pass away or encounter troubles, per the report. It’s also a status symbol for the wealthy and famous.”
Peraso Inc. (NASDAQ: PRSO ) reported that Panasonic System Networks R&D Lab adopted Peraso’s X710 chipset for its new 60GHz WLAN solution.
“Panasonic is a global consumer and enterprise technology leader and we are very excited that PSNRD, a Panasonic group company, has selected Peraso’s chipset for their latest 60 GHz WLAN solution,” stated Ron Glibbery, Peraso’s CEO. “We believe that the X710 is perfectly suited to meet PSNRD’s stringent demands and that their product, combined with Peraso’s robust technology, is delivering a highly desirable wireless connectivity solution.”
BioRestorative Therapies, Inc. (NASDAQ: BRTX ) stated that the U.S. Food and Drug Administration (“FDA”) cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy candidate, in treating chronic lumbar disc disease.
“The FDA clearance of this important amendment highlights our positive relationship with the agency, brings additional safety to our subject participants, and helps preclude the possibility of transient clinical outcomes in the control group, which can impact end of study readouts,” stated Lance Alstodt, BioRestorative’s Chief Executive Officer. “To further clarify, control patients in our Phase 2 clinical trial will now have a needle placed in close proximity to the target disc, but the disc will not be pierced, nor will it have saline injected into it. This positive change in our protocol will not have any impact from a timing perspective, affirming our already established 2024 enrollment completion target.”
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ) reported positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
“The positive Phase 3 results in MDD represent a significant step towards our goal of further establishing CAPLYTA as a first-choice treatment across mood disorders,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We believe that these robust efficacy results coupled with its favorable safety and tolerability profile and convenient dosing make CAPLYTA a compelling option as an adjunctive treatment for MDD, if approved. At ITCI, we are committed to bringing improved treatment options to patients with major neuropsychiatric conditions through our efforts to expand CAPLYTA’s label and advance our pipeline.”
The post Notable Newsmakers appeared first on 24/7 MarketNews .
For further details see:
Notable Newsmakers